Pure-play biosimilars developer Alvotech has raised US$300 million through a private bond offering that will be used to further develop its biosimilar assets, “fuel continued growth” and to refinance its existing debt.
“This successful financing transaction will help fund Alvotech’s plans for future growth and secure the financing of further biosimilar development...






